

ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Geminal dihalogen isosteric replacement in hydrated AI-2 affords potent quorum sensing modulators†

Cite this: DOI: 10.1039/x0xx00000x

Min Guo,^a Yue Zheng,^a Jessica L. Terell,^b Michal Ad,^a Clement Opoku-Temeng,^a, William E. Bentley,^b and Herman O. Sintim^{*a}

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Hydrated carbonyl groups in AI-2, a quorum sensing autoinducer, make key hydrogen bonding interactions in the binding site of LsrR (a transcriptional regulator). This can be recapitulated with geminal dibromides, via halogen bonding. Geminal dihalogens represent interesting isosteric replacements for hydrated carbonyls in ligands and are currently under-utilized in ligand design.

Quorum sensing in bacteria controls many processes, ranging from virulence factors production, pigmentation, biofilm formation, amongst others.¹ The QS process starts with the production of signal molecules called autoinducers (AIs) by QS synthases, followed by exportation into the extracellular media and the perception of the signal by either membrane bound receptors (e.g. LuxP in *Vibrios*) or intracellular (e.g. LuxR-type) QS receptors. The binding of autoinducers to these receptors, ultimately lead to the modulation of transcriptional activators or repressors. Although many classes of QS autoinducers exist, the three main ones that have been actively studied are the Gram-positive peptide,² Gram-negative acyl homoserine lactones³ and AI-2 (a mixture of interconverting isomers, see Figure 1), which is used by both Gram-negative and Gram-positive bacteria.⁴

AI-2 is complex and fascinating QS molecule. It is produced by many bacterial strains and either the molecule itself or its synthase, LuxS, affect the physiology (including biofilm formation)^{1b, 5} of multitudes of bacteria, some of which are of clinical and bioterrorism relevance, such as *Vibrio cholera*,⁶ *Yersinia pestis*⁷ and *Staphylococcus aureus*.⁸ AI-2 production, as well as its degradation, affects central metabolism and emerging data suggests that it could

^a Department of Chemistry and Biochemistry, University of Maryland College Park, 20742, USA.

^b Fischell Department of Bioengineering, University of Maryland, College Park, 20742, USA.

* Tel: +1 301 405 0633. Fax: +1 301 314 9121. E-mail: hsintim@umd.edu

† Electronic Supplementary Information (ESI) available: Experimental details including synthesis, NMR spectra, Mass and microbiological methods. See DOI: 10.1039/c000000x/




Figure 1. a) Biosynthesis of AI-2. b) Chemical structures of AI-2.

be used as an alternative carbon source to produce acetyl-CoA.⁹ From a chemical perspective, AI-2 shows remarkable diversity as a signaling molecule (see Figure 1 for the possible inter-converting isomers of AI-2) and depending on environmental conditions, AI-2 can exhibit selectivity in QS signaling. For example, in the presence of boric acid (such as in aquatic environment), AI-2 predominantly forms the boronate ester (4, Figure 1), which is a ligand for LuxP of *Vibrios*.⁴ Enteric bacteria, such as *E. coli* and *Salmonella* use AI-2, particularly after it has been processed by LsrK kinase.^{1b, 10} So far four different proteins that bind to AI-2 have been characterized: LuxP, which binds to a boronated form (4),⁴ LsrB (a transporter), which binds to the cyclic but non-boronated form (6),¹¹ LsrR, which binds to the phosphorylated linear form (and with the 3-position as the hydrate, 7)¹² and LsrF, which binds to the 1,3-diketo form of AI-


2 (10).⁹

Figure 2. a) 3-hydrated DPD (7) and 3,3-dihalogen analogs. **b)** Degradation of AI-2 via LsrG/LsrF. We expect that the geminal dihalogen analogs cannot form the 1,3-diketone intermediate (10) hence would not be degraded by LsrG/LsrF.

Due to the ubiquity of AI-2 in bacterial QS signaling, there is interest in developing small molecules that can modulate AI-2-based signaling.¹³ Anti-AI-2 small molecules (or AI-2 receptor antagonists) could be used in synergy with traditional antibiotics.¹⁴ AI-2-based agonists have the potential to be used as tools in synthetic biology to modulate systems that use AI-2-based circuits.¹⁵ Fruitful approaches to develop anti-AI-2 molecules have been the modifications of AI-2 at the C1,^{13a, 15-16} C4^{16c, 17} or C5-positions^{13f} (see Figure 1, DPD 1 or 7, for the carbon labeling) into analogs that have shown great promise as either anti-biofilm or synergistic antibacterial agents.¹⁴ LsrR is a response regulator that represses the transcription of many genes, including biofilm-related genes. Upon binding to phosphorylated AI-2, LsrR no longer binds to DNA and hence biofilm and virulence-related genes can be transcribed. Recently we revealed that LsrR actually bound to the 3,3-hydrated form of AI-2 (7, Figure 1).¹² We rationalized that isosteric replacement at the C3 position of AI-2 could prevent isomerization into the 1,3-diketone analog (10), which is a substrate for LsrF degradation (see Figure 2b).⁹




Figure 3. Phospho-AI-2 in its hydrated form at C3 when binding with LsrR (PDB code: 4L4Z). Asp243 is 2.7 Å from geminal diol unit of phospho-AI-2.

Analysis of interactions between P-AI-2 (phospho-3-hydrated DPD) and active-site residues in LsrR indicated that Asp243 was within 3Å of the geminal diol unit of AI-2 (see Figure 3), indicating that if Asp243 existed as the carboxylate form, then the hydrogens of the geminal diol could potentially form hydrogen-bonding

interactions with this residue. A geminal bromide or chloride, but not fluoride, could recapitulate this interaction via the halogen bond (strength of halogen bond is as follows: I > Br > Cl >> F).¹⁸ On the other hand, if the Asp243 is protonated in the active site, then it is conceivable that the carbonyl moiety could still partake in a halogen bond interaction with one of the geminal halogens whereas the carboxylic acid OH group would act as a hydrogen bond donor to the halogen.¹⁹ It is the ambivalence of higher halogens (presence of lone pairs for hydrogen bond formation and presence of a low lying $\sigma^*_{\text{C-X}}$ bond for halogen bond formation, see Figure S1)²⁰ that makes them ideal for isosteric replacement for the geminal diol.

Attempted synthesis of targeted dihalogen compounds 15-20 was fraught with difficulties because the final products were volatile (see Supporting Information, Scheme S1). Others and us have, however, demonstrated that ester “prodrug” versions of AI-2 are convenient sources of AI-2 because the esters can be easily purified on column chromatography and used directly in QS assays without prior deprotection of the esters.^{13b, 21} Presumably, esterases produced by bacteria hydrolyze the esters into the active compounds, obviating a need for ester unmasking prior to administration. Therefore we proceeded to make the ester “pro-drug” versions of compounds 15-20 as 31-36. Target compounds, 31-36 were synthesized using strategies shown in Scheme 1.

Scheme 1. Synthesis of dihalogenated AI-2 analogs.

With these molecules in hand, we investigated if they were non-toxic and could modulate quorum sensing in *E. coli*. Pleasingly, at 100 μM concentration, all of the compounds were non-toxic towards *E. coli* (see Figure S2). Using the *E. coli* strain LW7 (*LuxS* and harboring the β -gal gene), we could use the β -galactosidase assay (see SI, Figure S4) to evaluate our analogs.¹⁵⁻¹⁶ The β -gal gene in LW7 is under the control of the LsrR repressor. At high concentration of P-AI-2, the ligand binds to LsrR to dissociate it from the LsrR promoter region and therefore permit the transcription of the genes under the control of the LsrR repressor.²² We have previously reported that the size of the C1 alkyl group of AI-2 and analogs determines whether an analog would be an LsrR agonist or antagonist.^{16a} Recently a rationale for this observation was provided via the crystal structure of LsrR in complex with AI-2 or analogs.¹² Based on the LsrR crystal structure analysis, we postulated that the C1 methyl dihalogen analogs would act as agonists whereas the isobutyl dihalogen analogs would be antagonists, as long as the isosteric replacement of the geminal hydroxyl group with halogens did not adversely affect binding of the ligand to LsrR. Interestingly dibromo-AI-2 (35) and dichloro-AI-2 (33), but not difluoro-AI-2 (31), could induce β -gal transcription (analyzed via the β -galactosidase assay), see Figure 4a. In the absence of AI-2, the level of β -galactosidase is low whereas when 20 μM of AI-2 or dibromo-AI-2 (35) or dichloro-AI-2 were added (33) to LW7, the level of β -galactosidase increased (see activity assay in Figure 4a). Whereas the dibromo analog of AI-2 (35) was as potent as AI-2, the activity of the dichloro-AI-2 (33) was slightly lower than the native AI-2

molecule. In line with our expectation, none of the isobutyl dihalogen analogs were LsrR agonists, augmenting earlier observations that longer C1 chain AI-2 analogs are not agonists but are rather antagonists.^{12-13, 15-16}




Figure 4. a) AI-2 dependent β -galactosidase production of *E. coli* LW7 (*luxS*) in response to 20 μ M synthetic AI-2 or analogs. b) Analogs (20 μ M) inhibit native β -galactosidase production in *E. coli* LW7 (*luxS*) in the presence of 20 μ M synthetic AI-2.




Figure 5. AI-2 dependent EGFP induction in *E. coli* W3110 pCT6(*luxS*⁺) in response to difluoro-i-Bu-AI-2 (32), dichloro-i-Bu-AI-2 (34) and dibromo-i-Bu-AI-2 (36) (FACS analysis with microscopic image).

Isobutyl AI-2 (14) is a potent inhibitor of AI-2 signaling, via LsrR binding,^{12, 15-16} and has been shown to inhibit *E. coli* biofilm formation, either alone or in combination with traditional antibiotics, such as gentamicin.¹⁴ In fact isobutyl AI-2 (14) has a higher affinity for LsrR than AI-2; the dissociation constant, K_d , of AI-2/LsrR complex is 2.0 μ M whereas isobutyl-AI-2/LsrR has a K_d of 0.5 μ M.¹² Since the dichloro and dibromo mimics of AI-2 (33, 35) were

potent LsrR agonists, we wondered if the isobutyl-dihalogen would also be potent antagonists of LsrR. Interestingly both isobutyl dibromo and dichloro analogs of AI-2 were antagonists of LsrR (see Figure 4b). Whereas in the absence of these ligands 20 μ M AI-2 could induce β -gal expression, when equimolar amounts of isobutyl dibromo (36) or dichloro AI-2 (34) were added, these could compete with AI-2 and prevent β -gal expression above the background, see Figure 4b. Here too the isobutyl difluoro analog (32) was not an effective antagonist.

Next, we examined the effects of our analogs on *E. coli* W3110 pCT6 (*luxS*⁺), which contains an *egfp* gene under LsrR control (also see SI). Because W3110 pCT6 can make its own AI-2, in the absence of any AI-2 antagonist, about 90% of the population expressed the EGFP protein, see Figure 5. The addition of the dihalogenated isobutyl DPD analogs caused a reduction of the EGFP expression. In agreement with the β -gal assay (Figure 4), dibromo-iBu-AI-2 (36) was a better inhibitor than dichloro-iBu-AI-2 (34), which in turn was better than difluoro-iBu-AI-2 (32) (see Figure 5).




Figure 6. Molecular surface electrostatic potential of AI-2 and analogs in simplified models. Color ranges from -9.5 kcal/mol (red) to 9.5 kcal/mol (blue). Important atoms and σ -hole are labeled.

To explain our observations that the dibromo analog was a better mimic of hydrated AI-2 than the dichloro analog, which was also better than the difluoro analog, we compared the size (sterics) and electronics of the geminal dihydroxyl moiety with the various dihalogens in the cyclized and linear analog forms (see Figures S5 and Table S1). The space-filling models of AI-2 and its halogenated analogs (Figure S5) revealed that the fluoro analog (15) was smaller in size compared with AI-2 DPD (7) while both the chloro and bromo analogs, (17) and (19), were bigger than AI-2 DPD (7) (see Figure S5 and also Table S1).

Apart from size, electronics could also play an important role in ligand-receptor binding. Electrostatic potential surfaces for AI-2 and analogs (Figure 6 and Figure S6), in both linear and cyclic forms were calculated using Gaussian 09²³ at B3LYP/6-31G(d) level with solvent effect (water, PCM model). For chloro- and bromo- analogs, in both linear and cyclized forms, there is a region of positive potential at the opposite end of the C-X bond (on the halogen side). This positive region is called σ -hole, which is the basis of halogen bonding. So we speculate that chloro and bromo moieties in our analogs could function as electrophiles and partake in halogen bonding. Therefore even in the absence of hydroxyl groups, they could still interact with aspartic acid 243 in LsrR (see Figures 3 and S1). In the case of difluoro analogs, neither the size of fluoro moiety nor the electronics mimic the hydroxyl group well and hence the lack of activity (agonism or antagonism) seen with the difluoro substitution.

In conclusion, we have designed and prepared a new generation of AI-2 analogs with dihalogen at C3 position. This set of analogs exhibited similar bioactivities with our earlier generation of analogs with modified C1 but intact C3 but has the added advantage that isomerization into a 1,3-diketone, which facilitates LsrF degradation, is not possible. This work

demonstrates that geminal dihalogens, especially of higher halogens, are good mimics of hydrated moieties in biological ligands. It is expected that the substitution of geminal hydroxyl groups with dihalogen would afford molecules that could cross cell membranes more easily. Also for ligands whereby the hydrated form or keto form could facilitate degradation, such as in AI-2, isosteric replacement with dihalogens would provide more stable analogs. Geminal dihalogen-AI-2 adds to the increasing toolkit of small molecules that regulate bacterial phenotype.²⁴

We are grateful to NSF (CBET 1264509) and Camille Dreyfus Foundation (Teacher-Scholar fellowship to HOS) for funding. Yue Zheng is supported by Kraybill biochemistry fellowship and Ad Michal is supported by HHMI grant.

Notes and references

- (a)M. B. Miller and B. L. Bassler, *Annu Rev Microbiol*, 2001, **55**, 165-199; (b)J. Li, C. Attila, L. Wang, T. K. Wood, J. J. Valdes and W. E. Bentley, *J Bacteriol*, 2007, **189**, 6011-6020.
- A. Tomasz and J. L. Mosser, *Proc Natl Acad Sci U S A*, 1966, **55**, 58-66.
- A. Eberhard, A. L. Burlingame, C. Eberhard, G. L. Kenyon, K. H. Nealson and N. J. Oppenheimer, *Biochemistry*, 1981, **20**, 2444-2449.
- X. Chen, S. Schauder, N. Potier, A. Van Dorselaer, I. Pelczar, B. L. Bassler and F. M. Hughson, *Nature*, 2002, **415**, 545-549.
- P. E. Kolenbrander, R. J. Palmer, Jr., S. Periasamy and N. S. Jakubovics, *Nat Rev Microbiol*, 2010, **8**, 471-480.
- M. B. Miller, K. Skorupski, D. H. Lenz, R. K. Taylor and B. L. Bassler, *Cell*, 2002, **110**, 303-314.
- J. Yu, M. L. Madsen, M. D. Carruthers, G. J. Phillips, J. S. Kavanaugh, J. M. Boyd, A. R. Horswill and F. C. Minion, *Infect Immun*, 2013, **81**, 4053-4062.
- M. Li, A. E. Villaruz, V. Vadyvaloo, D. E. Sturdevant and M. Otto, *BMC Microbiol*, 2008, **8**, 4.
- J. C. Marques, I. K. Oh, D. C. Ly, P. Lamosa, M. R. Ventura, S. T. Miller and K. B. Xavier, *Proc Natl Acad Sci U S A*, 2014, **111**, 14235-14240.
- K. B. Xavier, S. T. Miller, W. Lu, J. H. Kim, J. Rabinowitz, I. Pelczar, M. F. Semmelhack and B. L. Bassler, *ACS Chem Biol*, 2007, **2**, 128-136.
- (a)S. T. Miller, K. B. Xavier, S. R. Campagna, M. E. Taga, M. F. Semmelhack, B. L. Bassler and F. M. Hughson, *Mol Cell*, 2004, **15**, 677-687; (b)J. S. Kavanaugh, L. Gakhar and A. R. Horswill, *Acta Crystallogr Sect F Struct Biol Cryst Commun*, 2011, **67**, 1501-1505.
- J. H. Ha, Y. Eo, A. Grishaev, M. Guo, J. A. Smith, H. O. Sintim, E. H. Kim, H. K. Cheong, W. E. Bentley and K. S. Ryu, *J Am Chem Soc*, 2013, **135**, 15526-15535.
- (a)C. A. Lowery, J. Park, G. F. Kaufmann and K. D. Janda, *J Am Chem Soc*, 2008, **130**, 9200-9201; (b)M. Guo, S. Gamby, S. Nakayama, J. Smith and H. O. Sintim, *Sensors (Basel)*, 2012, **12**, 3762-3772; (c)J. A. Gutierrez, T. Crowder, A. Rinaldo-Matthis, M. C. Ho, S. C. Almo and V. L. Schramm, *Nat Chem Biol*, 2009, **5**, 251-257; (d)J. F. Alfaro, T. Zhang, D. P. Wynn, E. L. Karschner and Z. S. Zhou, *Org Lett*, 2004, **6**, 3043-3046; (e)T. Zang, B. W. Lee, L. M. Cannon, K. A. Ritter, S. Dai, D. Ren, T. K. Wood and Z. S. Zhou, *Bioorg Med Chem Lett*, 2009, **19**, 6200-6204; (f)F. Rui, J. C. Marques, S. T. Miller, C. D. Maycock, K. B. Xavier and M. R. Ventura, *Bioorg Med Chem*, 2012, **20**, 249-256; (g)G. Brackman, A. A. Al Quntar, C. D. Enk, I. Karalic, H. J. Nelis, S. Van Calenbergh, M. Srebnik and T. Coenye, *Bioorg Med Chem*, 2013, **21**, 660-667; (h)M. Li, N. Ni, H. T. Chou, C. D. Lu, P. C. Tai and B. Wang, *ChemMedChem*, 2008, **3**, 1242-1249; (i)V. L. Malladi, A. J. Sobczak, T. M. Meyer, D. Pei and S. F. Wnuk, *Bioorg Med Chem*, 2011, **19**, 5507-5519; (j)V. Roy, B. L. Adams and W. E. Bentley, *Enzyme Microb Technol*, 2011, **49**, 113-123; (k)D. N. Quan and W. E. Bentley, *PLoS Computational Biology*, 2012, **8**, e1002637; (l)H. O. Sintim, J. A. I. Smith, J. Wang, S. Nakayama and L. Yan, *Future Med. Chem.*, 2010, **2**, 1005-1035.
- V. Roy, M. T. Meyer, J. A. Smith, S. Gamby, H. O. Sintim, R. Ghodssi and W. E. Bentley, *Appl Microbiol Biotechnol*, 2012, **97**, 2627-2638.
- S. Gamby, V. Roy, M. Guo, J. A. Smith, J. Wang, J. E. Stewart, X. Wang, W. E. Bentley and H. O. Sintim, *ACS Chem Biol*, 2012, **7**, 1023-1030.
- (a)V. Roy, J. A. Smith, J. Wang, J. E. Stewart, W. E. Bentley and H. O. Sintim, *J Am Chem Soc*, 2010, **132**, 11141-11150; (b)J. A. Smith, J. Wang, S. M. Nguyen-Mau, V. Lee and H. O. Sintim, *Chem Commun (Camb)*, 2009, 7033-7035; (c)K. Tsuchikama, J. Zhu, C. A. Lowery, G. F. Kaufmann and K. D. Janda, *J Am Chem Soc*, 2012, **134**, 13562-13564.
- M. Kadirvel, F. Fanimarvasti, S. Forbes, A. McBain, J. M. Gardiner, G. D. Brown and S. Freeman, *Chem Commun (Camb)*, 2014, **50**, 5000-5002.
- P. Metrangolo and G. Resnati, *Chemistry*, 2001, **7**, 2511-2519.
- E. T. Kool and H. O. Sintim, *Chem Commun (Camb)*, 2006, 3665-3675.
- K. E. Riley, J. Rezac and P. Hobza, *J Mol Model*, 2013, **19**, 2879-2883.
- M. Frezza, L. Soulere, D. Balestrino, M. Gohar, C. Deshayes, Y. Queneau, C. Forestier and A. Doutheau, *Bioorg Med Chem Lett*, 2007, **17**, 1428-1431.
- M. E. Taga, S. T. Miller and B. L. Bassler, *Mol Microbiol*, 2003, **50**, 1411-1427.
- Gaussian 09*, (2009) Gaussian, Inc., Wallingford, CT, USA.
- (a)R. J. Melander, M. J. Minvielle and C. Melander, *Tetrahedron*, 2014, **70**, 6363-6372; (b)R. J. Worthington, M. S. Blackledge and C. Melander, *Future Med. Chem.*, 2013, **5**, 1265-1284.